FDA Recall: 3 Infants Hospitalized with Botulism After Organic Formula

For healthcare providers, the recall of Nara Organics infant formula is a critical alert: infant botulism, though rare, remains a diagnostic challenge with potentially fatal consequences. With cases in California, Washington, and Pennsylvania, and all three successfully treated, the incident underscores the need for rapid recognition of symptoms like acute hypotonia and constipation in formula-fed infants, and for updated counseling on safe formula preparation to prevent future cases.

On June 14, 2026, the U.S. Food and Drug Administration announced that Nara Organics had voluntarily recalled all of its whole milk powdered infant formula products following the hospitalization of three infants diagnosed with infant botulism. The Centers for Disease Control and Prevention confirmed that each of the three babies had consumed Nara Organics Powdered Infant Formula, which is sold at Target stores nationwide and online through Target.com and Nara.com. The affected infants were in California, Washington, and Pennsylvania; all three were successfully treated and no deaths have been reported. This recall, while not linked to any positive tests for Clostridium botulinum in the finished product, represents a significant food safety event with broad implications for the formula industry, regulatory oversight, and pediatric healthcare.

“

botulinum tests in the three implicated lots—709125280E14F2, 709125288E14F2, and 708125174E14F2—is both reassuring and perplexing.

Infant botulism is a rare but life-threatening illness caused when C. botulinum spores colonize the intestinal tract and produce neurotoxins that block nerve function. Symptoms start subtly—constipation, poor feeding, lethargy, and a weak cry—before progressing to descending flaccid paralysis and potential respiratory arrest. The three infants in this cluster likely received treatment with botulism immune globulin intravenous (BIG-IV), which neutralizes the toxin and has reduced mortality to less than 1% when administered early. Their full recovery is a positive outcome, but the incident highlights the diagnostic challenge: botulism is often mistaken for sepsis or metabolic disorders, delaying specific therapy. For pediatricians and emergency room physicians, this recall reinforces the need to consider botulism in any formula-fed infant under six months presenting with hypotonia and acute constipation, especially in regions where multiple cases appear.

From a food safety perspective, the absence of positive C. botulinum tests in the three implicated lots—709125280E14F2, 709125288E14F2, and 708125174E14F2—is both reassuring and perplexing. It suggests that contamination may be intermittent or at very low levels, below the detection threshold of standard microbiological assays. The decision by Nara Organics to recall its entire whole milk powdered formula line, not only the lots consumed, indicates either an abundance of caution or an understanding that the root cause of contamination has not been isolated. This aggressive recall posture mirrors prior large-scale formula recalls, such as the Abbott Nutrition recall of 2022, which triggered a nationwide shortage and exposed the fragility of a market where three companies control over 90% of U.S. supply. Nara is a smaller, organic brand, but its presence in Target stores—a major retail channel—means the recall affects a broad inventory and could cause localized shortages, particularly if health-conscious parents already face tight formula availability.

The financial and reputational hit to Nara Organics is likely substantial. The company has offered automatic refunds for purchases made on its website between May and June 2026, and consumers who bought at Target can return products there for a refund. These refund processes, while customer-centric, will involve significant costs in product returns, logistics, and customer service. For Target, managing the recall across its roughly 2,000 U.S. stores presents a logistical exercise but also an opportunity to demonstrate reliability in product safety. The retailer may tighten its supplier quality verification protocols, potentially requiring more frequent third-party microbial testing for private-label or niche organic brands.